Oct 21, 2026 08:24AM
Oct 20, 2026 08:40AM
Oct 15, 2026 08:30AM
Oct 8, 2026 08:56AM
Oct 1, 2026 08:26AM
Sep 16, 2026 09:17AM
Sep 10, 2026 08:21AM Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar L
Sep 10, 2026 08:00AM
Aug 24, 2026 08:01AM
Aug 24, 2026 08:00AM
Aug 11, 2026 04:01PM
Aug 10, 2026 08:02AM
Aug 10, 2026 08:00AM
Jul 13, 2026 04:01PM Erasca reports Phase 1 data for ERAS-0015 in KRAS-mutant tumors
Jul 13, 2026 04:01PM
Feb 17, 2026 10:48AM
Jan 12, 2026 08:03AM
Nov 19, 2025 09:45AM
Aug 12, 2025 04:01PM
Jun 2, 2025 08:06AM
Jun 2, 2025 08:00AM Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
May 13, 2025 04:05PM
May 13, 2025 08:04AM
May 13, 2025 08:00AM
Mar 25, 2025 04:31PM
Mar 20, 2025 04:01PM
Nov 12, 2024 04:01PM
Oct 24, 2024 08:02AM Erasca, Inc (ERAS) Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
Oct 24, 2024 08:00AM
Sep 25, 2024 08:00AM
Aug 12, 2024 04:01PM
Jun 18, 2024 08:00AM
May 16, 2024 08:03PM
May 16, 2024 08:02PM
May 8, 2024 04:01PM Erasca Reports First Quarter 2024 Business Updates and Financial Results
Apr 24, 2024 04:05PM
Mar 27, 2024 04:01PM
Feb 14, 2024 08:01AM
Feb 14, 2024 08:00AM
Dec 11, 2023 08:03AM
Dec 11, 2023 08:00AM
Nov 28, 2023 08:00AM Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
Aug 10, 2023 04:01PM
Jun 22, 2023 04:01PM
Jun 22, 2023 04:01PM
May 25, 2023 05:00PM
May 15, 2023 04:01PM
May 1, 2023 08:03AM
May 1, 2023 08:00AM Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma
Apr 10, 2023 08:04AM

335,242 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All